Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
71.63
+0.09 (0.13%)
Dec 5, 2025, 4:00 PM EST - Market closed
Avidity Biosciences Revenue
Avidity Biosciences had revenue of $12.48M in the quarter ending September 30, 2025, with 434.03% growth. This brings the company's revenue in the last twelve months to $20.87M, up 106.27% year-over-year. In the year 2024, Avidity Biosciences had annual revenue of $10.90M with 13.99% growth.
Revenue (ttm)
$20.87M
Revenue Growth
+106.27%
P/S Ratio
517.20
Revenue / Employee
$53,371
Employees
391
Market Cap
10.79B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RNA News
- 15 days ago - These 15 stocks are still showing momentum — and a market-beating edge - Market Watch
- 16 days ago - Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 - PRNewsWire
- 25 days ago - Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights - PRNewsWire
- 5 weeks ago - Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) - The Motley Fool
- 5 weeks ago - 3 Investable Laggards In An Overbought Market - Seeking Alpha
- 5 weeks ago - Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA - Business Wire
- 5 weeks ago - Why Avidity Biosciences Stock Blasted 42% Higher Today - The Motley Fool
- 5 weeks ago - Avidity Biosciences Soars After $72 Per Share Novartis Takeover - Benzinga